Opens in a new tab

What Is Medication-Assisted Treatment (MAT), and Does It Work?

Pharmacist handing over a paper bag to a patient at a clinic counter, pills and bottles in the background.

Educational content only. This article summarizes publicly available information and is not medical advice. If you or someone you love is struggling with substance use, call SAMHSA's free, confidential helpline: 1-800-662-HELP (4357).

In brief: Medication-assisted treatment (MAT) uses FDA-approved medicines along with counseling to treat opioid or alcohol use disorder. Methadone, buprenorphine and naltrexone treat opioid addiction, and people on methadone or buprenorphine are less likely to die of an overdose. Naltrexone, acamprosate and disulfiram treat alcohol use disorder. These medicines are not simply a swap of one drug for another.

Medication-assisted treatment (MAT) is the use of FDA-approved medicines together with counseling and behavioral therapy to treat opioid or alcohol use disorder (SAMHSA). Yes, it works. People with opioid use disorder who take methadone or buprenorphine are less likely to die or to have an overdose than people who get no treatment (NIDA).

If someone has collapsed, had a seizure, has trouble breathing, or can’t be woken up, call 911 right away (MedlinePlus). If you have naloxone, give it, and see how to use naloxone (Narcan). Call 911 even after naloxone is given (FDA).

What is medication-assisted treatment, and what do MOUD and MAUD mean?

MAT means treating a substance use disorder with FDA-approved medicine plus counseling and behavioral therapy, which SAMHSA calls a “whole-patient” approach (SAMHSA). The medicines are chosen to fit each patient’s needs (SAMHSA).

SAMHSA now groups these medicines by the condition they treat:

  • MOUD (medications for opioid use disorder): buprenorphine, methadone, and naltrexone (SAMHSA).
  • MAUD (medications for alcohol use disorder): acamprosate, disulfiram, and naltrexone (SAMHSA).

These medicines ease withdrawal symptoms and cravings (SAMHSA). For opioids, they work for addiction to heroin, morphine, and codeine, and to oxycodone and hydrocodone (SAMHSA). If you are not sure what kind of care you need, see levels of care in addiction treatment.

How do methadone, buprenorphine, and naltrexone compare for opioid addiction?

All three are FDA-approved for opioid use disorder, and FDA says all three have been shown to be safe and effective (FDA). The biggest differences are how each one acts on the brain, where you get it, and how often you take it.

Methadone Buprenorphine Naltrexone
How it works A long-acting full opioid agonist that reduces cravings and withdrawal and blunts or blocks the effects of opioids (SAMHSA) A partial agonist; its opioid effects are weaker than methadone or heroin, and it eases withdrawal and cravings (SAMHSA) Blocks opioid receptors so opioids no longer cause pleasure; it is not an opioid and is not addictive (SAMHSA)
Where you get it Only from a SAMHSA-certified opioid treatment program (OTP) (SAMHSA) Many doctors, nurse practitioners, and physician assistants can prescribe it; no special clinic is needed (NIDA) Any health care provider can prescribe it (NIDA)
How often Taken daily (SAMHSA); stable patients may get up to 28 take-home doses (NIDA) Tablet or film once a day (MedlinePlus); extended-release shots and implants also exist (NIDA) A long-acting shot once a month (NIDA)
When you can start After you enroll in an OTP (SAMHSA) After at least 12 to 24 hours without opioids, in early withdrawal (SAMHSA) At least 7 days after short-acting opioids, or 10 to 14 days after long-acting ones (SAMHSA)

Methadone has been used for more than 50 years to treat opioid use disorder (NIDA). It acts on the same brain receptors as heroin and fentanyl, but more slowly, so it produces less intense pleasure while reducing withdrawal and cravings (NIDA).

Buprenorphine comes in tablets under the tongue, extended-release shots, and implants, and some products combine it with naloxone (NIDA). The naloxone is added to lower the chance of misuse (SAMHSA). Brand names include Suboxone, Zubsolv, Sublocade, and Brixadi (FDA).

Naltrexone for opioid use disorder is the extended-release shot (Vivitrol). The pill also blocks opioids, but only the shot is FDA-approved for this use (SAMHSA). Starting it is harder because a person usually has to stop opioids first (NIDA).

Which medicines treat alcohol use disorder?

Three medicines are approved in the United States for alcohol use disorder: naltrexone, acamprosate, and disulfiram (NIAAA). They help people stop or cut back on drinking and avoid going back to it (NIAAA).

Medicine How it helps Form
Naltrexone Helps reduce the urge to drink (NIAAA) A daily pill or a shot every four weeks (SAMHSA)
Acamprosate Eases the negative symptoms some people feel when they stop drinking, making it easier to stay sober (NIAAA) Pill (NIAAA)
Disulfiram Causes unpleasant symptoms if you drink alcohol (NIAAA) Pill (NIAAA)

A primary care provider can prescribe these medicines, and they can be used alone or with counseling (NIAAA). Naltrexone for alcohol is usually started after alcohol detox, to avoid strong side effects such as nausea and vomiting (SAMHSA). Alcohol withdrawal itself can be dangerous, so read about alcohol addiction signs, withdrawal, and treatment and medical detox vs. home detox.

Does medication-assisted treatment work?

Yes. Research shows methadone, buprenorphine, and naltrexone can reduce opioid use and other harms, and people on methadone or buprenorphine are less likely to die or overdose than people without treatment (NIDA).

In one NIDA co-funded study of 17,568 adults in Massachusetts who survived an opioid overdose, overdose deaths over the next 12 months fell by 59 percent for people taking methadone and 38 percent for people taking buprenorphine, compared with people not on medication (NIH). The study could not draw conclusions about naltrexone because too few people were taking it (NIH).

Outcome What the research found
Overdose deaths after a nonfatal overdose 59 percent lower with methadone and 38 percent lower with buprenorphine over 12 months (NIH)
Staying in treatment Both methadone and buprenorphine help people stay in treatment (NIDA)
HIV and hepatitis C risk Less injecting and sharing of injection equipment with methadone or buprenorphine (NIDA)
Wider benefits Better survival, more people keeping jobs, and better birth outcomes in pregnancy (SAMHSA)

Even so, less than 20% of people with opioid use disorder get these medicines (NIDA). NIDA lists distance from a clinic, pharmacies that don’t stock buprenorphine, and stigma as reasons (NIDA).

Isn’t MAT just trading one drug for another?

No. SAMHSA says these medicines are evidence-based treatments that do not just substitute one drug for another (SAMHSA). When taken as prescribed, methadone and buprenorphine prevent cravings and withdrawal without the intense “high” that other opioids cause (NIDA).

The body does become dependent on methadone and buprenorphine, as it can with many medicines (NIDA). Stopping suddenly can cause withdrawal, but it is milder than withdrawal from other opioids and can be managed by lowering the dose slowly (NIDA). To see what full opioid withdrawal is like, read understanding heroin addiction and withdrawal.

Naltrexone is not addictive because it blocks opioid receptors instead of activating them (NIDA). For alcohol, NIAAA says all approved medicines are nonaddictive and compares them to medicines for asthma or diabetes (NIAAA).

How do you get medication-assisted treatment?

Start with a doctor or nurse practitioner for buprenorphine or naltrexone, or an opioid treatment program for methadone. Since the Consolidated Appropriations Act of 2023, prescribers no longer need a special waiver (the “X-waiver”) to prescribe buprenorphine for opioid use disorder (SAMHSA). Any practitioner with a current DEA registration that includes Schedule III authority may now prescribe it, if state law allows (SAMHSA).

  • Buprenorphine: prescribed in regular doctor’s offices, and also given at certified opioid treatment programs (SAMHSA). It can even be started in the emergency department after an overdose (NIDA).
  • Methadone: you must enroll in an opioid treatment program (SAMHSA). At first, most people go in every day or almost every day (NIDA).
  • Naltrexone: any licensed prescriber can prescribe and give it (SAMHSA).
  • Telehealth: since the COVID-19 pandemic, providers can prescribe buprenorphine through telehealth (NIDA). Ask the provider which current federal and state rules apply to you.

SAMHSA’s FindTreatment.gov lists state-licensed treatment providers (SAMHSA). If you are trying to help someone else take this step, see how to talk to someone about their drug use.

How long do people stay on MAT?

People stay on MAT for as long as it helps them, which can be months or a lifetime. SAMHSA says these medicines are safe for long-term use, “ranging from months to a lifetime,” and that people should talk to their doctor before stopping (SAMHSA).

Medicine How long, per SAMHSA
Methadone At least 12 months; some people need long-term maintenance (SAMHSA)
Buprenorphine Tailored to each patient, and in some cases indefinite (SAMHSA)
Naltrexone for alcohol Treatment lasts three to four months (SAMHSA)

Do not stop suddenly. Stopping buprenorphine without your provider can cause withdrawal or a return to opioid use that could lead to overdose and death (FDA). Methadone doses are lowered slowly with a practitioner to prevent withdrawal (SAMHSA).

What are the side effects and safety risks of MAT?

The biggest safety risk is mixing these medicines with alcohol, benzodiazepines, or other sedating drugs. FDA labeling warns that taking Suboxone with other opioids, benzodiazepines, gabapentin or pregabalin, alcohol, or other central nervous system depressants can cause severe drowsiness, breathing problems, coma, and death (FDA). FDA also advises care when benzodiazepines are used with opioid addiction medicines (FDA).

Tell your provider about every medicine you take, including drugs like Xanax, Valium, or Klonopin (FDA). See our guide to benzodiazepines.

Medicine Side effects and risks to know
Methadone Serious breathing problems, especially in the first 24 to 72 hours and after dose increases; a rare heart rhythm problem called QT prolongation (MedlinePlus)
Buprenorphine Headache, stomach pain, constipation, trouble sleeping, and sweating (MedlinePlus); tooth decay and other dental problems with forms that dissolve in the mouth (FDA)
Naltrexone Nausea, vomiting, headache, dizziness, and anxiety (MedlinePlus); serious reactions at the shot site (SAMHSA)

Keep naloxone on hand. FDA labeling tells people on Suboxone to ask about naloxone or nalmefene for an emergency, including a child accidentally taking the medicine (FDA). Higher or repeated naloxone doses may be needed to reverse a buprenorphine overdose (FDA).

Know the overdose risk after naltrexone. After stopping naltrexone, a person can be more sensitive to opioids, and using opioids can lead to overdose and death (SAMHSA). Trying to overcome its blocking effect with large amounts of opioids can cause serious injury, coma, or death (SAMHSA). With fentanyl in the drug supply, read how much fentanyl it takes to overdose.

Store it safely. Liquid methadone is colored and can be mistaken for fruit juice, so lock take-home doses away from children (SAMHSA).

Pregnancy: methadone and buprenorphine are recommended for pregnant women with opioid use disorder (NIDA).

Sources

  1. Treatment Options for Substance Use Disorder, Substance Abuse and Mental Health Services Administration
  2. What Is Methadone?, Substance Abuse and Mental Health Services Administration
  3. What Is Buprenorphine?, Substance Abuse and Mental Health Services Administration
  4. What Is Naltrexone?, Substance Abuse and Mental Health Services Administration
  5. Waiver Elimination (MAT Act), Substance Abuse and Mental Health Services Administration
  6. Medications for Opioid Use Disorder, National Institute on Drug Abuse, 2025
  7. Methadone and buprenorphine reduce risk of death after opioid overdose, National Institutes of Health, 2018
  8. Treatment for Alcohol Problems: Finding and Getting Help, National Institute on Alcohol Abuse and Alcoholism
  9. Information about Medications for Opioid Use Disorder (MOUD), U.S. Food and Drug Administration, 2024
  10. FDA warns about dental problems with buprenorphine medicines dissolved in the mouth, U.S. Food and Drug Administration
  11. FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class, U.S. Food and Drug Administration
  12. Suboxone Drug Safety-related Labeling Changes, U.S. Food and Drug Administration
  13. Methadone, MedlinePlus, National Library of Medicine
  14. Buprenorphine and Naloxone Sublingual and Buccal, MedlinePlus, National Library of Medicine
  15. Naltrexone, MedlinePlus, National Library of Medicine

Frequently asked questions

About this article

This article is an educational summary written by the Drug Detox and Rehab editorial team. It is not medical advice. The information above was researched from the listed references.

Last reviewed: November 18, 2026. Need help? Call SAMHSA’s free, confidential helpline at 1-800-662-HELP (4357), available 24/7.